News

Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Apellis Pharmaceuticals (APLS)
Detailed price information for Lineage Cell Therapeutics Inc (LCTX-A) from The Globe and Mail including charting and trades.
6MGNX : 4 Analysts Assess Macrogenics: What You Need To Know
4 analysts have expressed a variety of opinions on Macrogenics MGNX over the past quarter, offering a diverse set of opinions ...
The Globe and Mail13d
Altimmune (ALT) Has a New Rating from B.Riley Financial
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart ...
Insider Monkey14d
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript
Operator: Thank you. [Operator Instructions] Our first question comes from Mayank Mamtani with B. Riley Securities. Please proceed with your question. Mayank Mamtani: Yes, good morning ...
Arrowhead Pharmaceuticals (ARWR) Receives a New Rating from B.Riley Financial
Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.
Q1 2025 PDS Biotechnology Corp Earnings Call
Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce ...
PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy
Q1 2025 Management View CEO Frank Bedu-Addo highlighted the initiation of the VERSATILE 003 Phase 3 clinical trial of Versamune HPV plus pembrolizumab for first-line recurrence and/or metastatic HPV16 ...
Seeking Alpha15d
PDS Biotech outlines expanded Phase 3 VERSATILE-003 trial with new Mayo Clinic sites as pipeline advances
Mayank Mamtani, B. Riley Securities: Asked about the impact of Keynote 689 neoadjuvant data on VERSATILE-003 enrollment. Dr. Kirk Shepard responded that "the Keynote 689 trial should not affect ...
Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs
Q1 2025 Management View Steven Lo, CEO, opened by highlighting the lifting of the stop work order on the 10,000 participant portion of Project NextGen Phase 2b COVID-19 vaccine trial, emphasizing, "we ...
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway
Altimmune's Q1 2025 earnings call highlights breakthroughs in NASH treatments, robust financials with a new $100M credit facility, and imminent Phase ...
Agenus signals near-term strategic transactions and operational cash burn target below $50M amid BOT/BAL data advances
Q1 2025 Management View CEO Garo Armen highlighted new BOT/BAL data validating durable responses in historically untreatable cold tumors, emphasizing, "we're talking about new data and more mature ...
Novavax projects $1.025B 2025 revenue framework with focus on partnerships
Q1 2025 Management View CEO John Jacobs highlighted the shift in Novavax's corporate strategy over the past year, transitioning from a primary focus on commercializing its COVID-19 vaccine to ...